Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDS (NCT00195000)
The purpose of this study is to find out how safe and effective the combination of the antibody-drug conjugate gemtuzumab ozogamicin (Mylotarg®; Pfizer/Wyeth-Ayerst Laboratories) in combination with cytarabine (DepoCyt®; Sigma Tau Pharmaceuticals) is in treating patients with Acute Myeloid Leukemia (AML) and advanced Myelodysplastic Syndrome over the age of 60 years.
This trial is sponsored by Weill Medical College of Cornell University. 
- Acute Myeloid Leukemia
- Myelodysplastic Syndrome
- Phase: II
- Enrollment: 43
- Start: May 2003
- Completion: February 2008
- Last verified: June 2013
Last Editorial review: July 21, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.